

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <u>Wright Joseph</u>  (Last) (First) (Middle) 1600 WEST MERIT PARKWAY  (Street) SOUTH JORDAN UT 84095  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MERIT MEDICAL SYSTEMS INC [ MMSI ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>CHIEF COMMERCIAL OFFICER</b>
	3. Date of Earliest Transaction (Month/Day/Year) 03/07/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, No Par Value	03/07/2024		M		25,000	A	\$28.2	67,223	D	
Common Stock, No Par Value	03/07/2024		S		25,000	D	\$75.677 <sup>(1)</sup>	42,223	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-qualified stock options (right to buy)	\$28.2	03/07/2024		M		25,000		04/14/2018 <sup>(2)</sup>	04/14/2024	Common Stock	25,000	\$0	0	D	
Non-qualified stock options (right to buy)	\$44.8							03/02/2019 <sup>(3)</sup>	03/02/2025	Common Stock	25,000		25,000	D	
Non-qualified stock options (right to buy)	\$55.73							03/01/2020 <sup>(4)</sup>	03/01/2026	Common Stock	30,000		30,000	D	
Non-qualified stock options (right to buy)	\$37.71							02/26/2021 <sup>(5)</sup>	02/26/2027	Common Stock	16,722		16,722	D	
Non-qualified stock options (right to buy)	\$56.25							03/19/2022 <sup>(6)</sup>	03/19/2028	Common Stock	9,681		9,681	D	
Non-qualified stock options (right to buy)	\$65.03							02/28/2023 <sup>(7)</sup>	02/28/2029	Common Stock	8,094		8,094	D	
Non-qualified stock options (right to buy)	\$70.58							02/28/2024 <sup>(8)</sup>	02/28/2030	Common Stock	13,576		13,576	D	

Explanation of Responses:

1. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$75.234 to \$76.220, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
2. Becomes exercisable in equal annual installments of 20% commencing on 04/14/2018.
3. Becomes exercisable in equal annual installments of 20% commencing on 03/02/2019.
4. Becomes exercisable in equal annual installments of 20% commencing on 03/01/2020.
5. Becomes exercisable in equal annual installments of 25% commencing on 02/26/2021.
6. Becomes exercisable in equal annual installments of 25% commencing on 03/19/2022.
7. Becomes exercisable in equal annual installments of 25% commencing on 02/28/2023.
8. Becomes exercisable in equal annual installments of 25% commencing on 02/28/2024.

/s/ Brian G. Lloyd, Attorney-in-Fact      03/08/2024

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**